Radiopharm Theranostics Future Growth
Future criteria checks 0/6
Radiopharm Theranostics is forecast to grow earnings and revenue by 28.6% and 79.7% per annum respectively. EPS is expected to grow by 35.9% per annum. Return on equity is forecast to be -42.3% in 3 years.
Key information
28.6%
Earnings growth rate
35.9%
EPS growth rate
| Biotechs earnings growth | 16.1% |
| Revenue growth rate | 79.7% |
| Future return on equity | -42.3% |
| Analyst coverage | Low |
| Last updated | 12 Mar 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2026 | N/A | -56 | N/A | -37 | 2 |
| 6/30/2025 | N/A | -48 | N/A | -32 | 2 |
| 6/30/2024 | N/A | -44 | N/A | -26 | 2 |
| 12/31/2023 | 6 | -47 | -24 | -23 | N/A |
| 9/30/2023 | 6 | -41 | -25 | -23 | N/A |
| 6/30/2023 | 6 | -35 | -25 | -23 | N/A |
| 3/31/2023 | 5 | -30 | -21 | -20 | N/A |
| 12/31/2022 | 4 | -26 | -18 | -17 | N/A |
| 9/30/2022 | 2 | -28 | -28 | -14 | N/A |
| 6/30/2022 | N/A | -30 | -38 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RAD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RAD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RAD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RAD is forecast to have no revenue next year.
High Growth Revenue: RAD is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RAD is forecast to be unprofitable in 3 years.